Technical Analysis for KRON - Kronos Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Historical KRON trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | -0.93% | |
| Hot IPO Pullback | Bullish Swing Setup | -0.93% | |
| Outside Day | Range Expansion | -0.93% | |
| Hot IPO Pullback | Bullish Swing Setup | 1.80% | |
| NR7 | Range Contraction | 1.80% | |
| Inside Day | Range Contraction | 1.80% | |
| New 52 Week Closing High | Bullish | -0.73% | |
| NR7 | Range Contraction | -0.73% | |
| Up 3 Days in a Row | Strength | -0.73% | |
| Up 4 Days in a Row | Strength | -0.73% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakdown | 3 days ago | |
| Down 2 % | 3 days ago | |
| Down 1% | 3 days ago | |
| Reversed from Down | 3 days ago | |
| Hot IPO Pullback Entry | 3 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Biopharmaceutical Biology Acute Myeloid Leukemia Enzymes Cancer Therapeutics Tyrosine Kinase Novel Cancer Entospletinib Kronos Morpholines Transcription Factors
Biopharmaceutical Biology Acute Myeloid Leukemia Enzymes Cancer Therapeutics Tyrosine Kinase Novel Cancer Entospletinib Kronos Morpholines Transcription Factors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 34.9 |
| 52 Week Low | 25.5 |
| Average Volume | 553,620 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 31.77 |
| Average True Range | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs ) | N/A |
| Chandelier Exit (Short, 3 ATRs ) | N/A |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 35.17 | ||||
| Resistance 3 (R3) | 35.18 | 34.41 | 34.79 | ||
| Resistance 2 (R2) | 34.41 | 33.83 | 34.41 | 34.66 | |
| Resistance 1 (R1) | 33.64 | 33.46 | 33.26 | 33.63 | 34.53 |
| Pivot Point | 32.87 | 32.87 | 32.68 | 32.87 | 32.87 |
| Support 1 (S1) | 32.10 | 32.29 | 31.72 | 32.09 | 31.19 |
| Support 2 (S2) | 31.33 | 31.92 | 31.33 | 31.06 | |
| Support 3 (S3) | 30.56 | 31.33 | 30.94 | ||
| Support 4 (S4) | 30.55 |
